Overview of clinical trials in CML - Not yet recruiting trials
Source: www.clinicaltrials.gov | Last update: September 2, 2026
On this page, you'll find a regularly updated list of not yet recruiting clinical trials focused on novel therapies - including study details, sponsors, estimated enrolment, locations and the number of study centres.
Download our searchable Excel file to filter by sponsor, compound, or trial phase
(Updated regularly; the current file is from September 2, 2026)
For an overview of currently recruiting clinical trials in CML, click here.
Disclaimer
The information presented in this overview has been sourced from www.clinicaltrials.gov and reflects data available as of September 2, 2026. While the iCMLf strives to ensure accuracy, it is not responsible for any errors, updates, or changes that may have occurred since that date. This list is provided solely for informational purposes and is organized alphabetically by investigational compound. The iCMLf does not endorse or recommend any specific clinical trial, investigational drug, or sponsor mentioned. For the most current and comprehensive details - including eligibility criteria, study locations, and contact information - please consult the official listing on clinicaltrials.gov.
Asciminib
Asciminib, with or without dasatinib combination, as a second-line therapy to ADVANCE the treatment for chronic myelogenous leukemia in chronic phase (ASC2ADVANCE)
The ASC2ADVANCE study evaluates whether asciminib alone or combined with dasatinib is an effective second-line treatment for chronic-phase chronic myeloid leukemia (CML-CP) patients whose first TKI therapy was unsuccessful or led to resistance. More information
Clinicaltrials.gov Identifier: NCT07538401
Compound: Asciminib
Sponsor: University Health Network, Toronto. dr.dennis.kim@uhn.ca
Status: Not yet recruiting (estimated enrolment: 45 participants)
Location (Centres): Location data not yet available
Efficacy of asciminib in real-world in patients with chronic myeloid leukemia in second or subsequent lines (ASCIRLI)
This real-world observational study evaluates the effectiveness, safety and tolerability of asciminib in patients with chronic-phase CML treated in second or subsequent lines, with a primary focus on achieving major molecular response (MMR). More information
Clinicaltrials.gov Identifier: NCT07640750
Compound: Asciminib
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto, p.fazi@gimema.it
Status: Not yet recruiting (estimated enrolment: 98 participants)
Location (Centres): Location data not yet available
A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region
(ASC4Young)
This real-world study evaluates the effectiveness and safety of asciminib in young adults with CML across the Gulf region using routinely collected clinical data.
More information
Clinicaltrials.gov Identifier: NCT07681258
Compound: Asciminib
Sponsor: Novartis Pharmaceuticals, novartis.email@novartis.com
Status: Not yet recruiting (estimated enrolment: 80 participants)
Location (Centres): Location data not yet available
Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
This Phase 1b/2 study evaluates the safety and efficacy of asciminib combined with FLAG-Ida and venetoclax in patients with advanced-phase CML or Ph+ AML, including its potential to achieve disease control and improve clinical responses. More information
Clinicaltrials.gov Identifier: NCT07604233
Compound: Asciminib
Sponsor: M.D. Anderson Cancer Center, fhaddad@mdanderson.org
Status: Not yet recruiting (estimated enrolment: 30 participants)
Location (Centres): USA (1)
Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML (ASIM-POST Ph+)
This clinical trial evaluates whether adding asciminib to TKI maintenance therapy after allogeneic stem-cell transplantation can safely reduce the risk of relapse and improve survival in patients with Ph+ B-ALL or blast-phase CML. More information
Clinicaltrials.gov Identifier: NCT07493408
Compound: Asciminib
Sponsor: The University of Hong Kong, Imk381@ha.org.hk
Status: Not yet recruiting (estimated enrolment: 45 participants)
Location (Centres): Hong Kong (1)
HS-10382
Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)
This study aims to evaluate the efficacy of adding asciminib to tyrosine kinase inhibitors (TKIs) in achieving treatment-free remission (TFR) for chronic-phase CML patients who previously failed a TKI cessation study. More information
Clinicaltrials.gov Identifier: NCT06530810
Compound: HS-10382
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. dr_huyu@126.com
Status: Not yet recruiting (estimated enrolment: 100 participants)
Location (Centres): China (exact site information not yet available)
TGRX-678
TGRX-678 Chinese Phase III in chronic myeloid leukemia (CML) patients
This phase III randomized multicenter trial compares the safety and effectiveness of TGRX-678 versus investigator-selected TKI therapy in chronic-phase chronic myeloid leukemia (CML-CP) patients who are resistant or intolerant to at least three prior TKIs. More information
Clinicaltrials.gov Identifier: NCT07489755
Compound: TGRX-678
Sponsor: Shenzhen TargetRx Co., Ltd.
Status: Not yet recruiting (estimated enrolment: 180 participants)
Location (Centres): China (exact site information not yet available)
TQB3911
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Phase I clinical trial to explore the safety, tolerability, and initial efficacy of TQB3911 tablets in BCR::ABL fusion gene positive leukemia. More information
Clinicaltrials.gov Identifier: NCT06672263
Compound: TQB3911
Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. jiangqian@medmail.com.cn
Status: Not yet recruiting (estimated enrolment: 120 participants)
Location (Centres): China (5)